BXMPY (Beximco Pharmaceuticals) 5-Year EBITDA Growth Rate: 14.40% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beximco Pharmaceuticals 5-Year EBITDA Growth Rate?

Beximco Pharmaceuticals BXMPY 93 5-Year EBITDA Growth Rate is 14.40% as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 6 warning signs investors should review.

Beximco Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2026 was $0.06.

During the past 12 months, Beximco Pharmaceuticals's average EBITDA Per Share Growth Rate was 21.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Beximco Pharmaceuticals was 28.70% per year. The lowest was -9.00% per year. And the median was 15.00% per year.

Beximco Pharmaceuticals  (OTCPK:BXMPY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Beximco Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms

BXMPY vs ZTS, UTHR: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.


Beximco Pharmaceuticals 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 14.40% mean?
Beximco Pharmaceuticals (BXMPY) has a 5-Year EBITDA Growth Rate of 14.40% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' 5-Year EBITDA Growth Rate too high?
Beximco Pharmaceuticals' current 5-Year EBITDA Growth Rate is 14.40%. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
Beximco Pharmaceuticals' 5-Year EBITDA Growth Rate of 14.40% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current 5-Year EBITDA Growth Rate is 14.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current 5-Year EBITDA Growth Rate of 14.40%. The current 5-Year EBITDA Growth Rate is 14.40%. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current 5-Year EBITDA Growth Rate is 14.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.